Specialty Pharmacy Network

Selected news for the healthcare topic - Specialty Pharmacy Network, collected since 11/2017. There are 82 items in the archive. This healthcare topic shares news with Excelera, Otsuka America Pharmaceutical, Paul Jardina and many others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies
Health Systems
People

Selected Headlines

Date Headline (link) Source Relevant Snippet
2/8/2022 NABP Specialty Pharmacy Accreditation Earns Optum Rx Globe Newswire MOUNT PROSPECT, IL, Feb. 08, 2022 (GLOBE NEWSWIRE) -- The National Association of Boards of Pharmacy ® (NABP ® ) is pleased to announce that its Specialty Pharmacy Accreditation has earned recognition from Optum Rx’s Specialty Pharmacy Network . This recognition deems NABP as an approved accrediting organization for pharmacies seeking specialty accreditation to qualify for participation in the Optum Rx Specialty Pharmacy Network .NABP’s Specialty Pharmacy Accreditation recognizes a pharmacy ...
8/19/2021 Onco360 Selected by Merck & Co., Inc. to Be in Specialty Pharmacy Network for WELIREG (belzutifan) financialbuzz.com Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.“Onco360 is honored ...
2/1/2021 Washington, DC, Feb. 01, 2021 (GLOBE NEWSWIRE) -- wapakdailynews.com Washington, DC, URAC, the nation’s largest independent health care accreditation organization and the recognized leader in pharmacy accreditation, has launched a first-of-its-kind partnership with Acentrus SpecialtyTM, the largest specialty pharmacy network for hospitals and health systems. The Acentrus network encompasses 111 hospitals and health systems nationwide, from major academic medical centers to community hospitals.“Hospitals and health systems are increasingly building specialty pharmacy capabilities and it ...
9/15/2020 Claritas Rx And Turning Point Form Partnership on Specialty Pharmacy Analytics salestechstar.com By STS News Desk Claritas Rx , a data integration and analytics company focused on specialty biopharmaceutical distribution channels, announced today that it has partnered with Turning Point , an innovative specialty pharmacy network comprised of the largest independent, top-performing specialty pharmacies, to provide biopharmaceutical manufacturers in-depth analytics and insight based on data from the Turning Point specialty pharmacy network . Read More: Birdie Announces Appointment Of Market Research Veteran Ted ...
9/14/2020 Claritas Rx And Turning Point Form Partnership on Specialty Pharmacy Analytics PR Newswire PRNewswire/ -- Claritas Rx, a data integration and analytics company focused on specialty biopharmaceutical distribution channels, announced today that it has partnered with Turning Point, an innovative specialty pharmacy network comprised of the largest independent, top-performing specialty pharmacies, to provide biopharmaceutical manufacturers in-depth analytics and insight based on data from the Turning Point specialty pharmacy network . "Claritas is the perfect partner due to the cultural fit and expertise," said ...
9/14/2020 Claritas Rx And Turning Point Form Partnership on Specialty Pharmacy Analytics Benzinga SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 /PRNewswire/ -- Claritas Rx, a data integration and analytics company focused on specialty biopharmaceutical distribution channels, announced today that it has partnered with Turning Point, an innovative specialty pharmacy network comprised of the largest independent, top-performing specialty pharmacies, to provide biopharmaceutical manufacturers in-depth analytics and insight based on data from the Turning Point specialty pharmacy network . "Claritas is the perfect partner due ...
9/14/2020 Claritas Rx And Turning Point Form Partnership on Specialty Pharmacy Analytics tmcnet.com ... Analytics SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 /PRNewswire/ -- Claritas Rx, a data integration and analytics company focused on specialty biopharmaceutical distribution channels, announced today that it has partnered with Turning Point, an innovative specialty pharmacy network comprised of the largest independent, top-performing specialty pharmacies, to provide biopharmaceutical manufacturers in-depth analytics and insight based on data from the Turning Point specialty pharmacy network . "Claritas is the perfect partner ...
7/22/2020 Indy Health Insurance Company Seeking Investor Partners PR Newswire ... move from surviving the current U.S. drug pricing crisis to thriving," said Ms. Atkinson. In addition, Indy Health Independent Preferred Network members will have better reimbursements, no restrictions to mail and an independent Preferred Specialty Pharmacy Network . Through Indy Health Insurance Company, Medicare-D plan independent pharmacies will ultimately be able to create their own formulary, medication therapy management services and negotiate their own rebates through an independently owned, sustainable ...
4/23/2020 Kyle Skiermont to join Prime Therapeutics as senior vice president, specialty pharmacy and home delivery services PR Newswire ... role. He will lead Prime's future strategy for specialty pharmacy and home delivery services. Skiermont will have responsibility for all aspects of the specialty pharmacy delivery channel including specialty product and clinical program development, specialty pharmacy network s and a specialty drug management model. He will bring his rich clinical experience and focus on patient experience to shape a specialty delivery approach designed to improve member quality, experience and value. His ...
3/24/2020 scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update gurufocus.com ... FUROSCIX near completion, the Company has begun to turn attention to pre-commercialization efforts. The Company will be focused on specific pre-commercialization activities including establishing a managed care advisory board, contracting with a specialty pharmacy network , and conducting market research to prepare FUROSCIX product messaging and positioning. These pre-commercialization activities will be staged as appropriate to efficiently follow FUROSCIX’s regulatory progress. As part of these efforts, the Company ...
3/24/2020 scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update financialbuzz.com ... FUROSCIX near completion, the Company has begun to turn attention to pre-commercialization efforts. The Company will be focused on specific pre-commercialization activities including establishing a managed care advisory board, contracting with a specialty pharmacy network , and conducting market research to prepare FUROSCIX product messaging and positioning. These pre-commercialization activities will be staged as appropriate to efficiently follow FUROSCIX’s regulatory progress. As part of these efforts, the Company ...
3/23/2020 ACR Advocates Against Payer Mandates on Specialty Pharmacy Acquisition of In-Office Treatments the-rheumatologist.org Scientist Development Award Winner Probes Ethnic Disparities in Lupus Blue Cross Blue Shield of Tennessee (BCBST) announced in fall 2019 that all specialty drugs would have to be acquired through the BCBST specialty pharmacy network as of Jan. 1, 2020. After hearing significant opposition from stakeholders, it pushed back the implementation date to July 1, 2020. If BCBST moves forward with this policy, the ACR is concerned that other payers ...
3/13/2020 mCig Inc. Signs Letter of Intent With Multi-State Licensed PCAB Accredited Compounding, Retail, and Specialty Pharmacy Network Globe Newswire JACKSONVILLE, FL, March 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- mCig, Inc. (MCIG), an innovative biotech company focused on development and commercialization of over the counter, science-driven, botanical nutrigenetics targeting the endocannabinoid system, medical devices, and research & development, today announced execution of a Letter of Intent (LOI) reflecting the Company’s strategic partnership with NJ based, Kaplan Group d/b/a Medical Home Pharmacy ( http://www.medicalhomepharmacy.com/ , https://www.youtube.com/watch?v=LWqRacr ...
3/13/2020 mCig Inc. Signs Letter of Intent With Multi-State Licensed PCAB Accredited Compounding, Retail, and Specialty Pharmacy Network newmediawire.com Share mCig Inc. Signs Letter of Intent With Multi-State Licensed PCAB Accredited Compounding, Retail, and Specialty Pharmacy Network Mar. 13, 2020 7:00 AM ET Source: mCig, Inc. JACKSONVILLE, FL - ( NewMediaWire ) - March 13, 2020 - mCig, Inc. (MCIG), an innovative biotech company focused on development and commercialization of over the counter, science-driven, botanical nutrigenetics targeting the endocannabinoid system, medical devices, and research & development, today announced execution of a Letter of ...
3/13/2020 mCig, Inc. (MCIG) Signs Letter of Intent marijuanastocks.com mCig Inc. Signs Letter of Intent With Multi-State Licensed PCAB Accredited Compounding, Retail, and Specialty Pharmacy Network mCig, Inc. (MCIG), an innovative biotech company focused on development and commercialization of over the counter, science-driven, botanical nutrigenetics targeting the endocannabinoid system, medical devices, and research & development, today announced execution of a Letter of Intent (LOI) reflecting the Company’s strategic partnership with NJ based, Kaplan Group d/b/a Medical ...
1/10/2020 FDA approves Blueprint’s stomach cancer therapy priced at $32,000 per month Physicians Weekly ... the therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor (GIST). Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage. The list price is not necessarily what patients ...
1/10/2020 FDA Approves Blueprint's Stomach Cancer Therapy Priced at $32,000 Per Month managedhealthcareconnect.com ... subset of patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage. The list price is not necessarily what patients ...
1/9/2020 FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month | News | WIN 98.5 wincountry.com ... the therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor (GIST). Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage. The list price is not necessarily what patients ...
1/9/2020 FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month | News | MIX-FM mymixfm.com ... the therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor (GIST). Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage. The list price is not necessarily what patients ...
1/9/2020 FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month wiky.com ... the therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor (GIST). Blueprint said it expects to make Ayvakit available through a limited specialty pharmacy network in the United States within a week, with a wholesale acquisition cost or list price of $32,000 for a 30-day supply, regardless of dosage. The list price is not necessarily what patients ...